Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum Resistant Epithelial Ovarian Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06321484
What this trial is testing

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian CancerRecurrent Ovary CancerOvarian Cancer+4 more
Dana-Farber Cancer Institute 18
Testing effectiveness (Phase 2)Study completedNCT01853644
What this trial is testing

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
Recurrent Epithelial Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Primary Peritoneal Cancer
Northwestern University 31
Large-scale testing (Phase 3)Study completedNCT02855944
What this trial is testing

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 349
Testing effectiveness (Phase 2)Active Not RecruitingNCT03113487
What this trial is testing

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Platinum-Resistant Primary Peritoneal Carcinoma
City of Hope Medical Center 29
Testing effectiveness (Phase 2)Study completedNCT02901899
What this trial is testing

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Northwestern University 45
Testing effectiveness (Phase 2)Study completedNCT00006028
What this trial is testing

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Not applicableLooking for participantsNCT07540403
What this trial is testing

Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma

Who this might be right for
Ovarian Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 50
Testing effectiveness (Phase 2)Ended earlyNCT00354601
What this trial is testing

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Wake Forest University Health Sciences 2
Testing effectiveness (Phase 2)Study completedNCT00081276
What this trial is testing

3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Who this might be right for
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial Cancer+1 more
National Cancer Institute (NCI) 48
Large-scale testing (Phase 3)Ended earlyNCT02641639
What this trial is testing

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum Resistant Ovarian Cancer
Mateon Therapeutics 70
Early research (Phase 1)Looking for participantsNCT06964009
What this trial is testing

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian CarcinomaRecurrent Ovary Cancer+1 more
Elizabeth Stover, MD, PhD 30
Large-scale testing (Phase 3)Study completedNCT00262990
What this trial is testing

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
Novartis Pharmaceuticals 829
Not applicableWithdrawnNCT00813254
What this trial is testing

Cost Utility Analysis in Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
M.D. Anderson Cancer Center
Early research (Phase 1)Active Not RecruitingNCT05617755
What this trial is testing

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Who this might be right for
Carcinoma, Ovarian EpithelialOvarian NeoplasmsFallopian Tube Neoplasms+6 more
Arsenal Biosciences, Inc. 19
Early research (Phase 1)Temporarily pausedNCT04840589
What this trial is testing

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Platinum-Resistant Ovarian Carcinoma+1 more
National Cancer Institute (NCI) 66
Early research (Phase 1)Study completedNCT02028117
What this trial is testing

Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients

Who this might be right for
Recurrent Platinum Resistant Ovarian Cancer
Akamis Bio 38
Testing effectiveness (Phase 2)Ended earlyNCT03587129
What this trial is testing

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
First Affiliated Hospital of Harbin Medical University 1
Large-scale testing (Phase 3)Looking for participantsNCT06855069
What this trial is testing

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hansoh BioMedical R&D Company 468
Testing effectiveness (Phase 2)Ended earlyNCT01962948
What this trial is testing

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer
Fox Chase Cancer Center 12
Testing effectiveness (Phase 2)WithdrawnNCT02948101
What this trial is testing

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
M.D. Anderson Cancer Center
Next Page